Elite Pharmaceuticals, Inc.
ELTP
$0.40
-$0.021-4.99%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -23.92% | 0.41% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -23.92% | 0.41% | |||
| Cost of Revenue | -22.82% | 3.43% | |||
| Gross Profit | -25.35% | -3.27% | |||
| SG&A Expenses | 20.17% | 15.07% | |||
| Depreciation & Amortization | 2.90% | -1.27% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.83% | 3.06% | |||
| Operating Income | -68.50% | -9.81% | |||
| Income Before Tax | -11.91% | -1,222.79% | |||
| Income Tax Expenses | -84.23% | 553.97% | |||
| Earnings from Continuing Operations | 1.31% | -1,892.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1.31% | -1,892.17% | |||
| EBIT | -68.50% | -9.81% | |||
| EBITDA | -60.81% | -8.96% | |||
| EPS Basic | 0.97% | -1,816.67% | |||
| Normalized Basic EPS | -10.71% | -1,220.00% | |||
| EPS Diluted | 0.97% | -1,816.67% | |||
| Normalized Diluted EPS | -10.71% | -1,220.00% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | -0.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||